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intRoDuction
Radiosensitization by nanomaterials has attracted significant 
interests in the last decade. In this context, our team has devel-
oped a novel radiosensitizing nanoparticle (NP) named AGuIX® 
that underwent extensive pre-clinical evaluation and was recently 
translated to Phase I evaluation in the clinic for the treatment of 
brain metastases and advanced cervical cancer.1 In this paper, 
we summarize the preclinical evidence that has supported the 
transfer of AGuIX to first in man clinical evaluation.
Radiotherapy (RT) is one of the main treatment options for 
patients suffering from cancer. Indeed, more than 50% of all 
cancer patients receive RT during their treatment. In some types 
of cancer such as breast or central nervous system (CNS) tumours, 
the utilization of RT can reach 80–90% of patients.2 Advances in 
RT have focussed on improving the positioning and precision 
of radiation fields to the tumour target and reducing the conse-
quential toxicities caused by irradiation of surrounding organs 
at risk.3 Contemporary RT techniques, such as intensity-mod-
ulated radiation therapy, volumetric-modulated arc therapy 
and image-guided radiation therapy (IGRT) have significantly 
improved tumour targeting,4 while another potential approach 
to improve therapeutic index is the use of radiosensitizers. This 
approach has been extensively explored over the past 40 years5 
but more recently high atomic number (Z) NPs such as gado-
linium (Z = 64),6 hafnium (Z = 72),7 platinum (Z = 78),8 gold 
(Z = 79)9 or bismuth (Z = 82) have been investigated.10 These 
elements, which are high electron emitters,11 have the capacity to 
act as radiosensitizers and amplify the effects of radiation when 
activated by photons of keV to MeV energies, electrons, neutrons 
or fast ions (>50 MeV amu–1).12,13 Effective radiosensitization by 
elements such as gold has been observed at concentrations as 
low as 10 µg gold/g body weight in mice,11 although these effects 
cannot be explained by macroscopic dose enhancement and are 
not fully understood yet.14 It has been proposed that nanoscale 
dose deposition leads to important formation of radical species 
in the vicinity of the NPs.15 Despite a significant number of 
pre-clinical studies reports demonstrating the potential efficacy, 
only two NPs have been translated to clinical radiosensitizers, 
namely NBTXR37 developed by Nanobiotix company (Paris, 
France), an hafnium-based intratumorally administered NP, and 
AGuIX developed by NH TherAguix company (Lyon, France), a 
gadolinium-based intravenously administered NP.16
Nanomedicine research is a relatively new field of research and 
innovation that has attracted much attention.17 However, despite 
significant research efforts, less than 100 nanomedicine based 
drugs have progressed to the market since the acceptance of 
liposomal doxorubicin in 1995.17 Challenges in translation to 
the clinic are mainly due to (i) difficulties in industrialization 
of synthesis and cGMP processes, (ii) non-suitable pharmaco-
kinetics with long retention in the body and low penetration in 
the tumours for largest nanomedicines, (iii) eventual toxicity. 
Most nanomedicines are soft (organic) NPs (liposomes, poly-
meric NPs…) designed for improvement of drug delivery 
especially in the field of oncology.18 In contrast, inorganic NPs 
display advantageous properties that widen their utilization 
as for instance magnetic and optical hyperthermia,19 medical 
imaging such as MRI for superparamagnetic compounds or CT 
for metallic core20 and radiosensitization.21 Currently, only iron 
oxide NPs have been used as contrast agents for MRI in the clinic 
(Endorem®, GastroMARK™, Resovist®), but most of them have 
been withdrawn from the market.22 Another superparamagnetic 
iron oxide agent (Feraheme®) is on the market but it is dedicated 
to the treatment of iron deficiency anaemia.23
The translation of inorganic NPs to the clinic is relatively new and 
complicated. These NPs can be administered locally in the case of 
(i) NBTXR3 (hafnium-based NPs) for prostate cancer, head and 
neck cancer, liver cancer, soft tissue sarcoma or rectum cancer7 
or (ii) Nanotherm® (iron oxide NPs) developed by MagForce for 
the treatment of glioblastoma by magnetic hyperthermia24 or 
intravenously such as (i) AuroShell (large core (silica) shell (gold) 
NPs of 155 nm) developed by NanospectraBioscience for photo-
thermal ablation of tumours,25 (ii) CYT-6091 (Pegylated gold 
NPs) developed by CytImmune designed for drug delivery,26 (iii) 
NU-0129 (gold NPs) developed by the Northwestern Univer-
sity and designed for nucleic acids delivery,27 (iv) Cornell dots 
(fluorescent polysiloxane nanoparticles) developed by Wiesner 
et al as an optical-PET imaging probe for melanoma28 and (v) 
AbstRAct
AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been 
recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical 
results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity 
tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive 
uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparti-
cles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations 
in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes 
with the second generation of AGuIX nanoparticles and the first preliminary results on human.
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AGuIX NPs (nanoparticles made of polysiloxane and gado-
linium chelates) for improving MRI diagnosis of solid tumours 
together with their treatment by radiation therapies (RT and 
particle therapy).29
Two of these inorganic nanoparticles (AGuIX and Cornell Dots), 
are ultrasmall nanostructures (hydrodynamic diameter <10 nm) 
that allow rapid renal elimination to avoid long retention in the 
body and eventual toxicity after intravenous (i.v.) administra-
tion.30 Larger systems such as AuroShell® have demonstrated a 
long residence time in organs including the liver and spleen after 
i.v. administration (>1 year), and even in the absence of toxicity 
in animal models, this could be a challenge for further devel-
opment.25 Moreover, studies have emphasized the higher effi-
cacy of ultrasmall nanoparticles to penetrate tumours, thanks to 
accumulation by the enhanced permeability and retention effect 
[enhanced permeability and retention (EPR) effect].31 However, 
these insights have been shown on animal models and have to 
be confirmed on humans where the EPR effect is known to be 
heterogeneous.32
AGuIX are sub-5 nm nanoparticles that were firstly described 
in 2011.33 They are composed of a polysiloxane matrix with 
gadolinium cyclic chelates covalently grafted on the inorganic 
matrix (Figure  1).33,34 AGuIX NPs have demonstrated very 
high radiosensitizing properties1 together with excellent MRI 
positive contrast properties thanks to the paramagnetic proper-
ties of gadolinium.35 A review on the preclinical results obtained 
with AGuIX technology was published in 2014 highlighting the 
most relevant preclinical evidence at that time.1 Since then, the 
synthesis process has been improved, regulatory toxicity tests 
have been performed and two clinical trials have been accepted 
by the French regulatory office ANSM (Agence Nationale de 
Sécurité du Médicament et des produits de santé):36
(i) NanoRAD (NCT02820454) for the treatment of brain 
metastases by whole brain radiation therapy in association 
with AGuIX NPs at Grenoble Alpes University Hospital.
(ii) NanoCOL (NCT03308604) for the treatment of locally 
advanced cervical cancer by chemoradiation and 
brachytherapy in association with AGuIX NPs at Institut 
Gustave Roussy, Villejuif.
The object of the present review is to focus on the new develop-
ments of the AGuIX nanoplatform and its translation to the clinic.
bioDistRibution AnD PhARmAcokinetic
Biodistribution and toxicity studies in healthy 
animals
AGuIX NPs display sub-5 nm hydrodynamic diameters, which 
enables renal elimination.37 Several biodistribution studies have 
been performed on healthy animals of different species (rodents 
Figure 1. (A) Schematic representation of AGuIX® NPs (gadolinium atoms in green are chelated in DOTAGA ligands grafted to 
polysiloxane matrix). (B) Hydrodynamic diameter (~3 nm) distribution of AGuIX NPs as obtained by dynamic light scattering. (C) 
ESI-MS measurements on AGuIX nanoparticles. A mass around 10 kDa is obtained for the particle. Inset is obtained after using 
deconvolution with a multiplicative correlation algorithm. (D) Zeta potential  vs  pH for AGuIX NPs. Adapted from.30 NPs, nano-
particles.
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and monkeys) under different conditions including: different 
administration methods, different administered concentrations 
and times of animals sacrifice after administration to better 
understand the behaviour of AGuIX NPs in the body.
To verify that AGuIX NPs are effectively eliminated by the 
kidneys, AGuIX NPs have been labelled by 111In and adminis-
tered intravenously in mice and animals were sacrificed 3 and 24 h 
after administration. In both cases, less than 0.15% of the injected 
dose is observed in organs other than kidneys and bladder.33 A 
more specific study on rodents using complementary techniques 
was performed to study the route of elimination.30 AGuIX NPs 
(8 µmol in gadolinium/animal) were administered intravenously 
to mice, which were then sacrificed at different time points and 
kidneys collected, epoxy-embedded and sliced for imaging by 
laser-induced breakdown spectroscopy (Figure 2A). This exper-
iment allows mapping and quantification of inorganic elements 
in biological samples.39 NPs were observed in the kidneys 5 min 
after administration and localised close to the cortex region. The 
maximum Gd signal was observed 4 h after administration while 
almost no signal could be obtained 1 week later. In other exper-
iments, AGuIX NPs were labelled with rhodamine and injected 
intravenously. The observation of the kidneys by intravital 
two-photon microscopy analysis, performed 5 min after admin-
istration, indicated that the NPs were observed in the renal blood 
vessels. Tubules were reached 1 h after administration and the 
signal remained detectable after 1 and 48 h. Only a weak signal 
was observed in some of the tubules 1 week after administra-
tion and was no longer visible 2 weeks later. Renal function was 
monitored by measuring the serum creatinine levels. A transient 
increase of the serum creatinine level was observed 30 min after 
administration most likely due to bolus injection.
In parallel to this study, AGuIX NPs were administered intra-
venously in cynomolgus monkeys and pharmacokinetics was 
monitored by MRI (Figure  2B).38 The same pattern of biodis-
tribution was observed for rodents. The vascular network and 
main organs (i.e. kidneys, heart and liver) were clearly identi-
fied. Haemodynamic, cardiac and ventilation parameters were 
monitored and no influence of bolus injection was detected. A 
large fraction of the nanoparticles was eliminated from the blood 
during the first 30 min and could be detected in the ureter as 
early as 150 s after administration. At the administered dose of 
200 mg kg−1 (1 mg of AGuIX NPs corresponds approximately to 
1 µmol of gadolinium), MRI images indicated a blood half-life of 
around 2 h. These two studies confirmed that renal elimination is 
the mechanism of AGuIX NPs clearance and that there is almost 
no uptake in other organs.
Regulatory toxicity and pharmacokinetics studies were 
performed in compliance with good laboratory practice on two 
animal species: rats (Wil Research company) and Cynomolgus 
monkeys (Wil Research company). In a dose response study, 
rats (16 animals/group) received two repeated i.v. injections 
(once a week during 2 weeks) at 250, 500 and 750 mg kg−1. For 
this evaluation, nanoparticles were formulated at pH 7.2 and 
dispersed in water 1 h prior to injection. No treatment-related 
clinical signs were observed during the follow-up period (14 
Figure 2. (A) Laser-induced breakdown spectroscopy analysis (Gd and Na) after i.v. administration (8 µmol) in mice. (B) MRI first 
pass kinetics of AGuIX NPs in a male monkey after iv injection of AGuIX NPs. Adapted from.30,38 NPs, nanoparticles.
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days) and no hypersensitivity reactions were reported, even after 
multiple injections at the highest doses. Dose escalation studies 
have also been performed in Cynomolgus monkeys, 3 doses were 
tested (150, 300 and 450 mg kg−1; 6 animals/group). A protocol 
consisting of twice repeated i.v. injection protocol was used 
(i.e. once a week during 2 weeks).38 No adverse clinical signs 
were observed during the treatment period. AGuIX NPs were 
well-tolerated and did neither affect neurological function nor 
cardiac and respiratory rates. Again, no hypersensitivity reaction 
was reported (absence of any cutaneous reaction, even at sites of 
injection). Only transient vacuolations of the renal tubules have 
been reported only in rodents, similarly to gadolinium chelates. 
The study with rodents indicated a no observable adverse effect 
level corresponding to an human equivalent dose of 120 mg kg−1 
approximately. In Cynomolgus monkeys, the 450 mg kg−1 dose 
corresponds to the no observable effect level. These studies have 
been used to determine the dose of AGuIX NPs administered 
during phase Ib clinical trials NanoRAD and NanoCOL that will 
determine AGuIX NPs tolerance in humans in association with 
RT and chemotherapy (NanoCOL for cisplatin).
Biodistribution and toxicity studies after i.v. 
administration in tumour-bearing animals
Due to the presence of gadolinium, AGuIX NPs provide MRI 
positive contrast agent properties. The observed longitudinal 
relaxivities rates are two to three times higher than clinically 
approved Gd-based contrast agents. MRI properties give insights 
into the pharmacokinetics and uptake in tumours.34 AGuIX NPs 
have been tested on different orthotopic tumour models of the 
CNS: (i) 9L gliosarcoma bearing rats,29,40 (ii) U87MG glioblas-
toma bearing mice41 and (iii) B16F10 brain melanoma metas-
tases bearing mice (Figure 3).16 In each case, tumour uptake was 
observed. It is due to the EPR effect. Interestingly, a retention time 
in the tumour significantly longer than the time of the molec-
ular agents like DOTAREM® was observed.42 Indeed, particles 
were still detected by MRI 24 h after their i.v. administration. 
This pharmacokinetic is fully adapted to clinical transfer since 
RT protocols include fractionation of radiation treatments over 
several days such as those used in NanoRAD trial (10 sessions 
of 3 Gy each for a 2 weeks duration). No evidences of AGuIX 
NPs extravasation in healthy brain tissue was observed. NPs 
were rapidly eliminated from the circulation, avoiding potential 
damages to healthy tissue, especially in the case of whole brain 
treatment where both tumour and normal tissue were irradiated.
To obtain more quantitative biodistribution data of AGuIX NPs, 
PET/MRI experiments were performed on U87MG hetero-
topic tumour bearing mice. AGuIX NPs were labelled with two 
different isotopes: a short-lived (68Ga, half-life 68 min)43 and a 
long-lived (89Zr, half-life 78 h)44 to study differential pharma-
cokinetics. Before radiolabelling, AGuIX NPs were functional-
ized by ligands known to have high affinity for the two isotopes 
Figure 3. Accumulation of AGuIX NPs in tumours of the CNS. (A) MRI and gadolinium quantification at different time points after 
administration of AGuIX NPs in 9L-gliosarcoma-bearing rats. (B) MR axial image of the brain before and after intravenous adminis-
tration of AGuIX NPs in U87MG tumour bearing mice. (C) T1 weighted image of the brain of a B16F10 tumour-bearing mouse after 
administration of AGuIX NPs. Adapted from,16,29 and.41 CNS, central nervous system; NPs, nanoparticles.
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(NODAGA for 68Ga and DFO for 89Zr). Radiolabelled AGuIX 
NPs displayed the same pattern of biodistribution. A rapid renal 
elimination resulting in extremely low background activity in 
all the tissues other than kidneys was observed. Further study 
with 68Ga showed an important increase of tumour-to-muscle 
ratio from 2.06 to 4.40 and 4.71 at 30, 60 and 120 min post-in-
jection (p.i.) respectively, indicating retention of labelled NPs in 
the tumour but elimination from the circulation.43 AGuIX NPs 
are biodegradable in diluted medium.45 A metabolites study 
performed by high-performance liquid chromatography  showed 
some degradation fragments only in urine, in contrast to blood 
and tumours where only entire nanoparticles were detected.43
After radiolabelling with 89Zr, tumour-associated radioactivity 
was evaluated after 24 and 72 h,44 and compared with molecular 
89Zr-DFO. At 24 hours p.i., the molecular agent displayed a signal 
in the tumour four times weaker than labelled AGuIX NPs (0.5 
and 2.0% ID/g respectively). Moreover, the AGuIX@89Zr tumour 
to muscle ratio increased from 4 (24 h p.i.) to values higher than 
10 after 72 h, thus validating the long-term retention of the NPs 
in the tumours.
The residence time of the NPs in brain tumours of 9LGS bearing 
rats was quantified by performing X-ray fluorescence of the 
tissues 1 and 24 h after i.v. administration.40 The presence of 
gadolinium was assessed and quantified by L-α emission line at 
6.0 keV and the quantity of AGuIX NPs in tumours found was 
close to 5.5 and 0.15 ppm at 1 and 24 h after i.v. administration 
respectively.
In addition to animals bearing CNS tumours, biodistribution 
imaging experiments have been performed on animals with 
pancreatic (capan-1),46 colorectal (CC531),47 chondrosarcoma 
(swarm rat chondrosarcoma),48 lung (Luciferase modified 
non-small cell lung cancer H358)35 and breast (4T1) tumours 
after i.v. administration of AGuIX NPs (Figure  4). As previ-
ously shown for tumours of the CNS, rapid tumour uptake was 
observed with a long retention time. Indeed, the NPs were still 
detected 24 h after i.v. administration in pancreatic,46 lung49 and 
breast cancer (Figure 4).
For example, a study was performed on mice bearing breast 4T1 
tumours using AGuIX NPs functionalized with NODAGA and 
64Cu (life time of 12.7 h). The signal in the tumour was rela-
tively stable from 5 to 48 h after injection (at around 2% ID g–1) 
confirming the long retention. As mentioned in the case of CNS 
tumours, long term retention is an important factor during frac-
tionated RT protocols used in clinic.
Alternative administration routes of AGuIX® NPs
Although i.v. administration is the preferred route of adminis-
tration for translation to the clinic, other routes have been tested 
with AGuIX NPs (Figure 5). Like for other inorganic nanomed-
icines (NBTXR3 and Nanotherm®), intratumoral (i.t.) admin-
istration of AGuIX NPs has also been explored.50 This route of 
administration can be used for highly accessible tumours and 
has the advantage to deliver the exact quantity of NPs to the 
tumour volume, which requires smaller quantities of material. 
AGuIX NPs have the advantage of being dispersible at very high 
Figure 4. (A) T1 weighted MRI of a pancreatic tumour bearing mouse after i.v. administration of AGuIX NPs. Yellow arrows indicate 
tumour localization. (B) T1 weighted image of hepatic colorectal cancer metastasis after i.v. administration of molecular agent 
(Gd-DOTA) and AGuIX NPs. Comparison of contrast-to-noise ratio and signal-to-noise ratio for Gd-DOTA and AGuIX NPs in 
tumour. (C) In vivo SPECT imaging in the paw of a swarm rat chondrosarcoma orthotopic model after i.v. administration of radiola-
belled 111In AGuIX NPs. (D) Ultrashort echo-time MRI axial slices of a lung tumour bearing mouse before and after i.v. administration 
of AGuIX NPs. (E) PET/CT imaging of a 4T1 tumour bearing mice after i.v. administration of radiolabelled 64Cu AGuIX NPs. Adapted 
from,35,46–48. i.v., intravenous; NPs, nanoparticles; SPECT, single photon emission computed tomography.
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concentration (500 g l−1), which allows delivery of large quanti-
ties in very small volumes. For example, i.t. administration of 1 
µmol of AGuIX NPs (in gadolinium) labelled by Cy 5.5 has been 
performed in nude mice bearing SQ20B tumours (Figure 5A). 
The whole tumour is fluorescent directly after administration 
and no change of the signal is observed for the first 15 min after 
administration. However, for translation to the clinic, additional 
studies are needed to demonstrate that this type of administra-
tion leads to a sufficiently homogeneous distribution of the NPs 
in the tumour and leakage of AGuIX NPs from the tumour to 
blood is likely to happen.
Another potentially interesting local administration is intraperi-
toneal (i.p.) delivery as recently shown by an independent study 
of Hu et al in a hepatocellular carcinoma model51 (Figure 5B). 
The biodistribution of the AGuIX NPs has been assessed after 
radiolabelling by 64Cu and animals sacrificing 9, 21 and 40 h 
after i.p. administration. Accumulation with high retention in 
the tumour was observed, with uptakes of 7.82 ± 1.50, 8.43 ± 
6.23 and 6.84 ± 1.40% ID g–1 at 9, 21 and 40 h respectively and 
with no significant accumulation in other normal tissues (except 
kidneys and bladder).
Our team has also studied administration via the airways in mice 
where we observed rapid passage from the lung tissue into blood 
circulation after intratracheal administration of NPs which was 
followed by renal elimination.52
An MRI pharmacokinetic study showed that the elimination 
half-time from the lungs is of the order of 130 ± 20 min inde-
pendently of the administered NPs concentration (10, 25 and 50 
mM in [Gd3+]).53 This value is significantly higher than the one 
obtained for DOTAREM (22 ± 5 min; 250 mM in [Gd3+]) and 
give access to a larger imaging window. The relatively rapid elim-
ination observed from the lungs for AGuIX NPs (hydrodynamic 
diameter <5 nm) is in good agreement with the previous study of 
Choi et al with quantum dots.54 Moreover, a short term toxico-
logical study was performed to evaluate adverse effects through 
this route of administration. In this preliminary study, no signif-
icant change in the number of inflammatory cells or in patholog-
ical changes in the alveolocapillary barrier were observed. These 
results further support translation to the clinic of AGuIX NPs.
When administered to orthotopic lung tumour bearing mice 
(Figure  5C),34 retention in the tumour was observed allowing 
non-invasive detection of millimetre-size tumours with excellent 
correlation between MRI signal, bioluminescence and histology. 
Using four times less gadolinium than i.v. administration (200 
µl, [Gd3+] = 50 mmol l−1), administration via the airways (50 
µl, [Gd3+] = 50 mmol l−1) resulted in two times higher values of 
signal enhancement and an increase in contrast-to-noise ratio. 
Higher signal in the tumour for the airways delivery can be 
explained by rapid passage of the NPs from the healthy tissues 
of the lung to the blood circulation and specific retention in the 
tumour tissue. Besides, after passage into the bloodstream, the 
NPs can be taken up by EPR effect. In the case of lung tumours, 
administration by airways may be more interesting since lower 
amounts of NPs are needed to reach therapeutic concentrations 
in the tumour. As illustrated in the orthotopic U87 glioblastoma 
study, this mode of administration may also be used to improve 
tumour diagnosis and treatment of other organs since NPs go to 
the circulation and concentrate in tumours via EPR effect.40
This novel delivery method can also be applied to image pathol-
ogies other than cancer such as idiopathic pulmonary fibrosis, a 
chronic, progressive and ultimately lethal disease.55 In this study, 
idiopathic pulmonary fibrosis has been induced by intratracheal 
administration of bleomycin that results in excessive fibro-
blast activation and extracellular matrix proliferation. Without 
contrast agent, MRI fails to delineate clearly the induced lesions 
but after intratracheal administration of AGuIX NPs, all lesions 
are clearly detected and delineated in animals. The elimination 
Figure 5. (A) Optical images of a head and neck SQ20B tumour bearing mouse after intratumoral administration of Cy 5.5 labelled 
AGuIX NPs. (B) Micro-PET images and biodistribution of HepG2 tumour bearing mice after intraperitoneal administration of radi-
olabelled 64Cu AGuIX NPs. Animals were sacrificed 9 h, 21 h and 40 h after intraperitoneal administration of the NPs and radio-
activity was quantified. (C) MRI and 3D optical images at different time points after administration via the airways of AGuIX NPs 
labelled by Cy 5.5 in orthotopic NSCLC tumour bearing mice. Adapted from.49–5150 3D, three-dimensional; PET, positron emission 
tomography.
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times of the NPs from the lungs were determined by MRI. As 
observed in two different models (C57BL/6 and BALB/c), longer 
elimination times were measured for injured animals (250.6 ± 
22 and 249.7 ± 26.1 min) in comparison with healthy animals 
(166.3 ± 6.3 and 159.6 ± 13.6 min). These different elimination 
rates allow injured lung to be distinguished from healthy tissue. 
More generally, studying the pharmacokinetics and elimination 
of AGuIX NPs in the lungs may contribute to the detection of 
lung injuries.
AGuIX NPs have also been recently tested for magnetic reso-
nance lymphography (MRL) after intradermal injection on 
a chronic lymphedema model of the rat hindlimb.56 In addi-
tion to imaging of the lymphatic vessels, MRL can give access 
to lymph node characterization. Contrary to most of the other 
compounds tested for MRL (dendrimers, dextran, hepatobi-
liary contrast agents…), AGuIX NPs do not exhibit delayed 
renal elimination and uptake into the mononuclear phagocyte 
system. In this study, AGuIX NPs were injected intradermally in 
the left hindlimb and Gd-DOTA (DOTA: 1,4,7,10-Tetraazacy-
clododecane-1,4,7,10-tetraacetic acid) as a control (Figure  6). 
Both contrast agents highlighted the popliteal lymph node 
with enhancing signal as early as 15 min after administration. 
AGuIX NPs administration was associated with an about two 
times higher signal-to-noise ratio in comparison with molecular 
Gd-DOTA. In contrast to Gd-DOTA, signal enhancement did 
not drop to baseline but persisted up to 90 min after administra-
tion. Moreover, due to a higher hydrodynamic diameter (around 
3 nm), AGuIX NPs were mostly drained from the injection site 
into the lymphatic vessels. Contrary to AGuIX NPs behaviour, 
Gd-DOTA was drained both by the short saphenous vein and 
lymphatic vasculature resulting in images being more difficult 
to analyse by the overlaying venous enhancement. This study 
emphasizes the potential interest of AGuIX NPs for MRL after 
reconstructive lymphedema surgery or for lymph node detection.
RADiosensitizAtion
Although AGuIX NPs provide excellent imaging, they were 
initially developed as radiosensitizers in the context of image-
guided radiotherapy. As previously reviewed,1 AGuIX NPs have 
shown radiosensitizing efficacy in vitro on a various number of 
cell lines with typical sensitizer enhancement ratios varying from 
1.1 to 2.5 for photon irradiation at different energies ranging 
from keV to MeV. Sensitizer enhancement ratios are defined 
Figure 6. Comparison of lymphadenography with AGuIX NPs and Gd-DOTA. Scale bars: 9.5 mm. Copyright from.56 NPs, 
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as the survival fraction ratios for the control cells (irradiation 
alone) to those of the treated cells (irradiation combined with 
nanoparticles). This radiosensitizing effect cannot be explained 
by macroscopic dose enhancement alone. In addition, model-
ling of the radiosensitization can be explained by nanoscale dose 
deposition in the vicinity of the nanoparticles. Such modelling 
has been performed after irradiation at 80 keV (Figure 7).57 The 
clustering of a few gadolinium atoms leads to the formation of 
an Auger shower inducing a strong increase of the deposited 
dose close to the gadolinium cluster. However, more theoretical 
studies are needed to more clearly determine the exact mecha-
nism of action of AGuIX NPs in association with RT. Correlating 
MRI enhancement and local clinic response will be of particular 
importance to answer this point during clinical studies.
In vitro
In particular, the radiosensitizing effects of AGuIX NPs on clin-
ical irradiators at 6 MV have been demonstrated in a number 
of cell lines including cervical carcinoma – HeLa (incubation 
at [Gd3+] = 0.5 mM) (SER4Gy = 1.3; Dose Enhancement Factor 
(DEF) = 1.2),57 glioblastoma–U87MG (SER from 1.10 to 1.50 
for concentrations ranging from 0.1 to 0.5 mM)58 and pancreatic 
adenocarcinoma–panc1 (DEF = 1.30) (incubation at [Gd3+] = 
0.5 mM) (Figure 8).46,59 The DEF is the ratio of the area between 
the survival curves with and without NPs.
New mechanisms for radiotherapy in association 
with AGuIX NPs
Investigations have been performed to better understand cell 
death mechanism of RT in combination with AGuIX NPs.
A recent study in radioresistant head and neck squamous cell 
carcinoma (HNSCC) SQ20B cells aimed to understand the 
radiosensitizing mechanisms in presence of AGuIX NPs.61 
Using 250 kV X-Rays, a surviving fraction at 4 Gy of 1.382 was 
obtained with an enhanced biological factor of 1.3 (incubation 
of cells at 0.8 mM in gadolinium). According to a previous study 
on U87MG glioblastoma cells,58 AGuIX NPs are shown to prin-
cipally localize in lysosomes with no particles detected in the 
nucleus. To demonstrate the importance of ROS production in 
the mechanism of AGuIX NPs radiosensitization, depletion of 
glutathione (GSH), an endogenous ROS scavenging system was 
tested on SQ20B cells. After treatment, a net increase in ROS 
production was observed when irradiation was combined with 
AGuIX NPs (incubation of cells at 0.8 mM in gadolinium) and 
resulted in an increase of enhanced biological factor from 1.3 to 
1.6. Interestingly, autophagy and/or autophagic cell death signifi-
cantly increased after irradiation in combination with AGuIX 
NPs.
Radiosensitization with protons and other ions
An alternative to photon irradiation is the use of fast ion beams 
(70–400 MeV amu–1) to treat solid tumours (proton therapy and 
hadrontherapy when protons and carbon ions are used respec-
tively). These irradiations are generally proposed for the treat-
ment of tumours located in highly sensitive tissues such as eyes 
and brain, and also for paediatric cancers or highly radioresis-
tant tumours.62 Ion irradiation offers better tumour targeting in 
comparison with conventional X-ray radiation due to specific 
high energy delivery at the end of the track (Bragg peak). This 
prevents damages to the healthy tissues located behind the 
tumour volume. The induction of low but significant damages 
in the healthy tissues located in front of the tumour remains a 
major limitation. The fast development of particle beam facili-
ties all around the world has increased the interest in developing 
agents capable of improving the performances of this treatment 
modality. In particular, it has been demonstrated that the addi-
tion of high-Z nanoagents increases the effect of ion beam radia-
tion.13 This allows to use NPs to amplify the effects in the tumour 
and to decrease the total dose given to the patient, so decreasing 
adverse effects to healthy tissues. Moreover, as for conventional 
RT, the use of multimodal NPs (good electron emitters also 
active in medical imaging modalities—MRI for instance) offers 
the possibility to develop “image-guided particle therapy”.
The efficiency of AGuIX NPs to amplify the effects of medical 
protons was demonstrated using a 150 MeV proton beam under 
two irradiation conditions mimicking the entrance (0.44 keV 
µm–1) and the end (3.6 keV µm–1) of the proton track63 on 
plasmid pBR322. In particular, it was demonstrated that the 
yields of complex damages (nanosize breaks lethal for the cells) 
is amplified for irradiation in association with AGuIX NPs. More 
Figure 7. (A) Schematic formation of electron showers and reactive oxygen species obtained after irradiation. (B) Simulation of 
the deposited dose after irradiation at 2 Gy. Adapted from.57
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importantly, this increase was found to be more important at the 
end of the proton track than at its entrance (from amplification 
factorcomplex =1.19 ± 0.06 at 0.44 keV µm–1, to 1.32 ± 0.04 at 3.6 
keV µm–1) (incubation of plasmids at 0.04 mM in gadolinium). 
When the same experiment was performed in the presence of 
dimethyl sulfoxide, a radical scavenger, an important decrease of 
the damage yield was observed, confirming the role of hydroxyl 
radicals in the radiosensitization associated with protons. 
Similar experiments were realized using He2+ and C6+ and led 
to the same conclusions as for those with photons (i.e. increase 
of lethal damages when irradiation is associated with AGuIX 
NPs in comparison with control groups: amplification factorcom-
plex of 1.45 and 1.73 for He2+ and C6+ respectively). The increase 
is more pronounced for incident C6+. Like for irradiation with 
protons, the major role of hydroxyl radicals in the radiosensi-
tization of particle beam treatment associated with AGuIX NPs 
was evidenced.
In addition to nanoscale evidence of the AGuIX NPs efficiency 
to amplify particle beam effects, in vitro experiments confirmed 
the amplification of cell killing using various models: (i) Chinese 
ovary cell (CHO) line (incubation of cells at 1 mM in gado-
linium)64 (ii) three HNSCC cell lines: SQ20B, Cal33 and FaDu 
(incubation of cells at 0.8 mM in gadolinium) (Figure 9).65 In the 
case of CHO cells loaded with AGuIX NPs, enhancing factors 
of 11.3 and 18.5% for He2+ and C6+ respectively were found. By 
fitting the survival curves by the linear quadratic law (S(D) = 
exp (-αD–βD2), it was found that AGuIX NPs did not signifi-
cantly change the yield of sublethal damages (β = 0.044 with 
He2+, and 0.047 with C6+ respectively) but significantly increased 
the induction of directly lethal damages (α = 0.17 vs  0.22 for 
control and AGuIX NPs with He2+ respectively and α = 0.19 vs 
0.27 for control and AGuIX NPs with C6+ respectively). Thus, the 
increasing of the α/β ratio demonstrates an enhancement of the 
radiation lethality when AGuIX NPs are associated to the treat-
ment. These results have been confirmed by irradiation with C6+ 
of three cell lines of HNSCC known for their radioresistance. Like 
for CHO, the β coefficient remained nearly unchanged between 
the control and the cells loaded with AGuIX NPs whilst the α 
coefficient increased significantly (0.42 vs 0.56 for SQ20B, 0.38 vs 
0.56 for Cal33 and 0.51 vs 0.64 for FaDu). Here again, an increase 
of the relative biological effectiveness was observed for the three 
cell lines when irradiation was performed in association with 
AGuIX NPs in comparison with irradiation alone (1.7 vs 1.27 for 
SQ20B, 1.7 vs 1.14 for Cal33 and 1.66 vs 1.33 for FaDu). All these 
data emphasize the synergistic benefits of combining particle 
therapies (proton therapy and hadrontherapy) with AGuIX NPs 
and the potential for further translation to the clinic.
Radiosensitization in different in vivo models
AGuIX NPs have already shown their efficiency as a radio-
sensitizer for different in vivo preclinical models of cancer 
Figure 8. Survival of HeLa cells (A, B) or panc1 cells (C, D) after irradiation with 220 kV (A, C) or 6 MV (B, D) with or without AGuIX 
NPs at different doses. Adapted from59 and.60
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(glioblastoma,29,33,40 brain metastases,16 melanoma,1 pancre-
atic cancer,46,66 liver cancer,51 chondrosarcoma, head and neck 
cancer50 and lung cancer49 ) (Figure 10). A particular attention 
has been paid to tumours of the CNS with studies on 9L glio-
sarcoma bearing rats and B16F10 melanoma brain metastases 
bearing mice. As previously said, after i.v. administration ([Gd3+] 
= 40 mM, 1.4 ml), a rapid uptake in the tumour was observed 
(as early as 5 min after administration) due to the EPR effect. 
Retention of the nanoparticles in the tumour for more than 24 
h was assessed in brain tumour models after i.v. administra-
tion. The quantity of gadolinium in the tumour was evaluated 
at 5.5 and 0.15 ppm in the tumours of 9L gliosarcoma bearing 
rats 1 and 24 h after i.v. administration of AGuIX NPs respec-
tively. Even if the quantity of gadolinium in the tumour was 
reduced at 24 h after administration, a superior mean survival 
time (MeST) was observed after irradiation by microbeam radi-
ation therapy at 24 h (95.5 days) in comparison with irradiation 
performed 1 h after administration (62 days) or without admin-
istration of nanoparticles (46 days) (Figure 10). This corresponds 
to Increases in Lifespan (ILS) of 130, 210 and 377.5% for irra-
diation only, irradiation at 1 and 24 h after i.v. administration 
respectively. Interestingly, the radiosensitizing effect seemed to 
be more significant 24 h after administration even if the quantity 
of nanoparticles in the tumour is smaller. This can be explained 
by the fact that the nanoparticles that remained in the tumours 
have a particular affinity for the tumour cells and are either 
strongly absorbed on the cell membrane or internalized, further 
potentiating their radiosensitizing effect. To assess the interest of 
these NPs for clinical translation, an experiment was carried out 
using a clinical irradiator (6 MV) and the same animal model 
(i.e. 9l gliosarcoma bearing rats).33 In this experiment, two irra-
diations were performed at day 10 and day 17 after implantation 
of the tumours. Each of the irradiations was performed 7 h after 
the i.v. administration of AGuIX NPs ([Gd3+] = 100 mM, 1 ml). 
With this protocol, MeST of 26 ± 0.5 days, 39 ± 0.5 days and 72.9 
± 35.5 days were observed for the controls, the irradiation only 
group and irradiation in combination with AGuIX NPs.
To compare the effects of AGuIX NPs with commercial molec-
ular gadolinium chelate (DOTAREM, Guerbet), an experiment 
comparing both compounds was proposed.42 Due to the rapid 
elimination of DOTAREM from the tumours, the irradiation by 
microbeam radiation therapy was performed 20 min after i.v. 
administration for each group in 9L gliosarcoma tumour bearing 
rats. The two groups with irradiation performed after i.v. admin-
istration of DOTAREM ([Gd3+] = 40 mM, 1.4 ml and [Gd3+] = 
1 M, 56 µl) presented similar MeST (32 and 43 days) to the irra-
diated only group (44 days) corresponding to ILS of 68, 126 and 
131%. In comparison, irradiation in association with AGuIX NPs 
nanoparticles ([Gd3+] = 40 mM, 1.4 ml) led to MeST of 102.5 
days corresponding to an ILS of 439%. This result was consistent 
with in vitro experiments and simulations that emphasize the 
importance of the nanoparticle structure of the radiosensitizer 
that is responsible for not only the nanoscale dose deposition (in 
the very close vicinity of the NP), but also the EPR effect that 
is responsible for long retention of nano-objects in tumours. To 
assess the use of AGuIX NPs on a different model of cancer in 
the CNS, a study was conducted on melanoma B16F10 brain 
metastases tumour bearing mice.16 In this study, the irradiation 
was performed 3.5 h after i.v. administration of the nanoparticles 
Figure 9. Survey of CHO (A), SQ20B (B), Cal33 (C) and FaDu (D) under irradiation by hadrons at different doses with or without 
AGuIX NPs. Adapted from62 and.65
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Figure 10. Radiosensitization on different preclinical models. (A) Survival curves obtained for 9LGS bearing rats. (B) Survival 
curves obtained for B16F10 brain metastases bearing mice and irradiation at 7 Gy. (C) Survival curves obtained for capan-1 tumour 
bearing mice under preclinical (220 kV) irradiation. (D) Survival curves obtained for capan-1 tumour bearing mice under clinical 
(6 MV) irradiation. (E) Relative tumour progression after intratumoral administration of AGuIX NPs in A375 tumour bearing mice. 
(F) Relative tumour evolution after intratumoral administration of AGuIX NPs in SQ20B tumour bearing mice. (G) Survival fol-
low-up in a rat xenograft model of chondrosarcoma (SWARM). (H) Survival curve obtained for H358-luc tumour bearing mice after 
administration of AGuIX NPs by the airways. (I) 18F-FDG PET quantitative evaluation before and after irradiation of hepatocellular 
carcinoma HepG2 tumour bearing mice. Adapted from,1,16,40,46,49–51.18F-18-fludeoxyglucose.
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(10 mg), when the imaging study indicated the highest quantity 
of gadolinium in the tumour. For this experiment, a preclinical 
irradiator was used (320 kV) with a single irradiation at 7 Gy. 
This model was very aggressive, with a MeST of 12 days for the 
control group, 13 days for the irradiation only group and 15 
days for the irradiation in association with AGuIX NPs, corre-
sponding to ILS of 8.3 and 25% for the irradiated group and 
irradiated in association with the AGuIX NPs group respectively 
(Figure 10). These encouraging results on two different models 
of brain cancer have led to the NanoRAD clinical trial ( Clini-
calTrials. gov Identifier: NCT02820454) that is designed to treat 
multiple brain metastases by whole brain radiation therapy in 
association with AGuIX NPs.
In parallel to these studies on tumours of the CNS, a complete 
study on pancreatic cancer (capan-1) was published in 2016 
comparing the efficacy of AGuIX NPs in association with 
preclinical irradiation (220 kV) or clinical irradiation (6 MV) 
(Figure 10C,D).46 Irradiation at a dose of 10 Gy was performed 
15 min after administration of AGuIX NPs (0.25 mg of AGuIX 
NPs g–1 of animal). This irradiation time was determined by 
MRI. This study showed the greatest signal in the tumour 15 min 
after i.v. administration (Figure 4). For pre-clinical irradiation, 
MeST of 13, 35 and 60 days were obtained for control group, irra-
diated only group and irradiated in association with AGuIX NPs 
group, corresponding to ILS of 169 and 361% for irradiated only 
group and combined treatment group respectively. An analysis of 
double strand DNA breaks after the death of the animals showed 
a significant increase of DNA damages for irradiation performed 
in combination of AGuIX NPs (~80 %) in comparison with irra-
diated only animals (~60 %) and control animals (<10 %). No 
significant DNA damages were observed for other organs like 
kidneys, liver, heart or lung, even if they are close to the irradi-
ation site (liver and kidneys). Interestingly, similar efficacy was 
obtained for clinical irradiation with MeST of 30, 60 and 93 days 
for control group, irradiated only group and irradiated in asso-
ciation with AGuIX NPs group corresponding to ILS of 100 and 
210% for irradiated only group and combined treatment group, 
respectively. This study was in good agreement with the study on 
9L gliosarcoma bearing rats34 and confirmed the in vivo potential 
of AGuIX NPs with clinical irradiation.
Other studies were published using an i.t. administration of 
AGuIX NPs. It was tested on radiosensitive (A375 melanoma)1 
and radioresistant (head and neck SQ20B cancer)50 models 
subcutaneously implanted on the flank of mice. For A375 mela-
noma tumour bearing mice, two irradiations (10 Gy each, 220 
kV) were performed just after the administration of the nanopar-
ticles (4 µmol of gadolinium) to avoid any escape of nanoparti-
cles from the tumour. Compared with untreated mice, tumour 
growth delay was observed for both irradiated mice without the 
presence of AGuIX NPs and those irradiated in association with 
AGuIX NPs, with much longer delay seen for irradiation in the 
presence of AGuIX NPs (Figure 10E). For example, 25 days after 
the treatment, the tumour volume increased only by 3% when 
the treatment was performed after AGuIX NPs administra-
tion, but increased by 82% in absence of AGuIX NPs. For the 
radioresistant model (head and neck cancer), an i.t. injection (1 
µmol of gadolinium) was also performed followed by an imme-
diate irradiation (320 kV) at 10 Gy (Figure  10F). Once again, 
tumour growth was delayed in comparison with the irradiated 
only group, due to decreased cell proliferation associated with 
increased apoptosis. For example, at the end of Week 7, the mean 
tumour growth was 5 times smaller than for the irradiated only 
group and 11 times smaller than for the control group. Another 
study has been performed on radioresistant chondrosarcoma 
in a rat xenografted model (SWARM). 5 min after i.t. admin-
istration of 100 µl (10 mM) of AGuIX NPs, a 4 Gy irradiation 
was performed. A statistical significant difference (Log Rank 
(Mantel-Cox) test <0.02)) was observed between the two studied 
groups (irradiated only group and irradiated in association with 
AGuIX® NPs group) (Figure 10G). These studies emphasize the 
potential of combining intratumorally administered AGuIX NPs 
with irradiation for the treatment of radioresistant cancers.
For some cancers, local delivery can be achieved by other types 
of administration. For example, delivery of nanoparticles via the 
airways demonstrated high tumour targeting capacity as shown 
by MRI and fluorescence imaging.35 To demonstrate the interest 
of this administration pathway for treating lung cancer, AGuIX 
NPs were nebulized in H358-Luc orthotopic lung tumour 
bearing mice ([Gd3+] = 40 mM, 1.4 ml). At 24 h post-administra-
tion, the animals were irradiated at 10 Gy (220 kV) (Figure 10H). 
No significant difference was observed between the irradiation 
only group and the control group, with MeST of 77 and 83 days 
respectively. In comparison, when the irradiation is performed 
in presence of AGuIX NPs, a MeST of 112 days was observed 
corresponding to an ILS of 35 and 45%  vs  the control group 
and the irradiation only group respectively. This method of 
administration offers the benefit of delivering a higher amount 
of nanoparticles in the tumour with a smaller total quantity of 
administered nanoparticles.
In an independent study performed by Hu et al51 AGuIX NPs 
were administered by i.p. pathway for hepatocellular carcinoma 
(HepG2 tumours) resulting in tumour uptake of 7.82 ± 1.50, 8.43 
± 6.23, and 6.84 ± 1.40% ID g–1 at 9, 21 and 40 h after adminis-
tration. The animals were initially irradiated at 1 h after admin-
istration (250 kV, 6 Gy) and a second irradiation was delivered 
after 24 h. 1 day after this treatment, tumour metabolism was 
measured by 18-fludeoxyglucose positron emission tomography 
imaging and maximum standard uptake value were obtained in 
regions of interest (Figure  10I). A decrease of 18-fludeoxyglu-
cose uptake in the tumour was observed for all the irradiated 
mice. Maximum standard uptake value (Before/After) of 1.03 
± 0.03, 1.04 ± 0.04 and 1.24 ± 0.02 were observed for control 
group and mice irradiated after administration of 1 mg and 10 
mg of AGuIX NPs respectively. Thus, no significant difference 
was observed after administration of 1 mg of AGuIX NPs but 
when the administered dose is sufficient (10 mg), irradiation 
suppresses glucose metabolism. These two examples highlight 
the interest of different administration pathways as a function of 
the type of cancer.
To conclude on this part, AGuIX NPs have already shown their 
potential for combination with RT in the treatment of cancer for 
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different animal models with a range of radiation sensitivities. 
Different administration pathways can be used. They include i.v. 
administration that only requires classical medical practice as 
well as local ones that permit the uptake of larger quantities of 
AGuIX NPs. But the latter will necessitate complementary regu-
latory studies for eventual clinical translation.
new GeneRAtion oF AGuiX® nAnoPARticles
Different modifications have been made to AGuIX NPs to develop 
ultrasmall polysiloxane-based NPs for improved or new appli-
cations: adding new metals on the NPs or functionalizing them 
with therapeutic or targeting moieties. This paper is focused on 
ultrasmall nanoparticles passively targeted to the tumours and 
therefore, studies aiming at actively targeting AGuIX NPs to 
tumour or other pathologies won’t be described.67–71 Targeted 
AGuIX NPs will be of great interest to increase uptake (<1% of 
the injected dose in animal models) and retention in the tumours.
Addition of new metals
As shown previously for radiolabelling, ligands can be covalently 
grafted on AGuIX NPs to enable further chelation of metals. In 
the case of AGuIX NPs, gadolinium acts as a contrast agent and 
a radiosensitizer thanks to its high atomic number (Z = 64), but 
other metals having higher Z such as gold (Z = 79) and bismuth 
(Z = 83) present potentially a more effective interaction with 
irradiation.11 The addition of bismuth on the AGuIX NPs (Bi@
AGuIX) can increase their efficacy for radiosensitization and also 
for CT.10 Bi@AGuIX NPs were obtained by grafting additional 
DOTA chelates on AGuIX NPs followed by the complexation of 
bismuth in acidic conditions. DOTA ligands were chosen due to 
their high affinity for Bi3+ (log K = 30.3).72 The final nanoparti-
cles displayed a hydrodynamic diameter of 4.5 nm and around 
10 DOTA chelated with Gd3+ and 5 DOTA chelated with Bi3+. 
Phantom measurements for MRI and CT led to a detection limit 
of 0.1 mg ml−1. At 7 T, Bi@AGuIX NPs displayed longitudinal 
relaxivity of 4.87 s−1.mM−1 and r2/r1 of 1.46, which is slightly 
higher than commercial contrast agents. For CT, a contrast of 
4.26 Hounsfield unit mM−1 was obtained, close to those of clin-
ically used CT contrast agents. To assess the in vitro radiosen-
sitizing properties of Bi@AGuIX NPs, A549 NSCLC cells were 
incubated with Bi@AGuIX (incubation of cells at 0.5 mM in 
gadolinium) NPs 30 min before irradiation with a clinical irradi-
ator (6 MV). When cells are incubated with Bi@AGuIX NPs, an 
increase in γH2AX and 53BP1 foci (Figure 11A,B) was observed 
associated with a significant decrease in the clonogenic survival 
of cells resulting in a DEF of 1.99 (Figure 11C).
After i.v. administration, the NPs were followed by CT and MRI 
in A549 lung adenocarcinoma tumour bearing mice. Their phar-
macokinetics was assessed by sacrificing the animals 30 min, 1, 
6 and 24 h after i.v. injection (Figure 11D) and quantifying Gd 
and Bi by ICP-MS. The results were similar for gadolinium and 
bismuth showing the integrity of the NPs, a rapid uptake in the 
tumour and an elimination via the kidneys with no significant 
retention in other organs. The irradiation (10 Gy, 6 MV) was 
performed 30 min after i.v. administration of Bi@AGuIX NPs at 
420 mg kg−1 (dry weight) when the tumour uptake was maximum 
(3.54% ID). The two control groups showed a rapid progression 
of the tumour (Figure  11E) with survival more than 70 days 
after therapy (Figure 11F). For the irradiated group, a delay of 
the tumour growth was observed during the first 30 days after 
irradiation followed by a rapid growth of the tumour resulting in 
no survival 80 days after irradiation. For the group irradiated in 
presence of the Bi@AGuIX NPs, a clear increase in both tumour 
growth delay and survival was observed (Figure 11E,F). Double 
strand DNA breaks were evaluated 30 min after irradiation for 
Figure 11. In vitro and in vivo experiments related to Bi@AGuIX NPs. (A) Qualitative visualization of γH2AX and 53BP1 foci in vitro 
irradiation of A549 adenocarcinoma cells under 6 MV irradiation. (B) Quantitative measurement of the number of γH2AX and 
53BP1 foci per cell after irradiation. (C) Clonogenic assay after irradiation of A549 cells under irradiation at different doses with or 
without Bi@AGuIX NPs. (D) Biodistribution of Bi@AGuIX NPs after iv. administration in A549 tumour bearing mice evaluated by 
quantification of Gd and Bi by ICP/MS after sacrifice of the animals at different time points. (E) Evaluation of the tumour growth 
after treatment for A549 tumour bearing mice. (F) Survival curves obtained after the treatment A549 tumour bearing mice for 
the different groups. Adapted from.10
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both healthy and tumour tissues. For healthy tissues, no increase 
of double strand DNA breaks was observed for any groups. For 
the tumours, an increase of double strand DNA breaks was 
observed both for the irradiated only group (67.31 ± 11.36 %) 
and the group combining Bi@AGuIX NPs and irradiation (89.33 
± 14.3%) in comparison with both control groups (8.1 ± 4.3 and 
5 ± 4.3% respectively).
As shown in this study, the addition of different metals like 
bismuth can provide other modalities to the AGuIX NPs without 
changing neither their size nor their biodistribution (i.e. renal 
elimination and tumour uptake). Other metals such as europium 
or terbium can also be added, thus offering fluorescent proper-
ties to the nanoparticle while radioactive isotopes can be used for 
PET or SPECT imaging as well as for brachytherapy.
Functionalization by photosensitizers
The functionalization of AGuIX NPs can also provide other ther-
apeutic modalities to the resulting nanoparticles, e.g. photody-
namic therapy (PDT).
PDT is an alternative therapy of cancer. This technique involves 
the use of a photosensitizer (PS) which under illumination by 
light generates cytotoxic reactive oxygen species such as singlet 
oxygen.73 The first generation of PDT agents were limited by 
photosensitivity of the patients due to weak differentiation 
between healthy and diseased tissues. Improved biodistribution 
can be obtained by coupling the photosensitizers to nano-objects 
that can target the tumour by the EPR effect and/or targeting 
moieties and that will not extravasate into healthy tissues.74 In 
addition, to obtain an absorption of light in the near infrared 
region, photosensitizers are usually hydrophobic and can easily 
aggregate in biological media, significantly limiting the injected 
concentrations and modifying their photophysical properties. 
The use of hydrophilic nanocarriers can overcome this limitation 
either by protecting the photosensitizers in the core of the object 
or by displaying them at their surface.75
Our strategy was to graft photosensitizers on AGuIX ultrasmall 
NPs to obtain hydrophilic NPs displaying smaller size than most 
of the nanostructures developed for PDT. Moreover, the MRI 
contrast properties of AGuIX NPs can be useful to clearly delin-
eate the tumour, to guide positioning of the optical fibres used in 
interstitial PDT (iPDT) and to optimize the drug-light interval. 
To demonstrate the potential of AGuIX NPs for iPDT, we have 
recently published a study on the treatment of glioblastoma (U87) 
bearing rats by iPDT in association with PS@AGuIX NPs.76 For 
this proof of concept, a well-known PS: a monocarboxylic TPP 
(a derivative from tetraphenylporphyrin) was grafted on the 
AGuIX NPs by carbodiimide chemistry. After grafting the PS, no 
significant changes in its photophysical properties (i.e. quantum 
yields of fluorescence and 1O2 production) were observed. After 
i.v. administration, tumour uptake was observed by MRI as early 
as 5 min after i.v. administration due to the passive targeting of 
the tumour by EPR effect. For light treatment, an optical fibre 
was placed stereotactically in the tumour of each rat and the 
position was confirmed by MRI (Figure 12A). The illumination 
of the tumour by light was performed 1 h after i.v. administra-
tion of AGuIX NPs (Figure 12B). For the treated group, inflam-
matory effects were observed 1 day after treatment by MRI with 
vasogenic and cytotoxic oedema. These inflammatory effects 
were not observed for the control group (i.e. illumination with 
AGuIX NPs without PS). Interestingly, for the treated group 
two different profiles of response were observed in the evolu-
tion of the diameter of the tumours after treatment, leading to 
the distinction between a responder and a non-responder group 
(Figure 12C,D). To explain the different tumour response between 
the two groups, a light dosimetry study was performed by Monte 
Carlo simulation based on the positioning of the optical fibre 
and the scattering of the photons. Based on these simulations, 
Figure 12. (A) Optical fibre insertion monitored by T2 weighted MRI. (B) Survival curves obtained after illumination for control and 
PS@AGuIX NPs-treated groups.(C) Survival curves obtained after illumination for control, non-responder and responder groups. 
(D) Relative growth of the tumour diameters for the different animals and determination of non-responder and responder groups. 
(E) Relative levels of metabolites measured by MRS 1 day after treatment. (F) Relative levels of metabolites measured by MRS two 
days after treatment. (G) Relative levels of metabolites measured by MRS 3 days after treatment. Adapted from.76 MRS, magnetic 
resonance spectroscopy; NPs, nanoparticles.
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it was determined that only the responder group received suffi-
cient illumination.76 A study of relevant intracellular metabo-
lites was also performed by magnetic resonance spectroscopy: 
choline containing components (Cho), creatinine (Cr), N-acetyl 
aspartate, lipid such as CH/CH2/CH3 levels, myo-inositol (Min), 
glutamate plus glutamine, and taurine (tau). Before treatment, all 
groups displayed the same metabolic signature (i.e. comparable 
levels of metabolites). Just after treatment, no significant differ-
ence was observed between the three groups but interestingly 
differences in metabolite levels were observable as soon as one 
day after treatment (Figure 12E) and these differences increased 
during the first three days after treatment (Figure  12F,G). An 
increase in lipid levels was observed that is usually correlated to 
membrane breakdown. By contrast, a decrease of the levels of 
Min and Cho was observed. For Cho, the decrease of the levels 
was correlated with rapid cellular membrane turnover. Min is 
an indicator of microglial activation and proliferation while its 
decrease is linked to proliferation shutdown.
These data show the potential of grafting standard PS like 
porphyrins to ultrasmall NPs. Their pharmacokinetics after 
grafting to AGuIX NPs is superior to those of molecular porphy-
rins, with no aggregation, elimination by the kidneys and uptake 
in the tumours by EPR effect. Moreover, the PK can be followed 
by MRI enabling the detection of the tumour, the monitoring 
of the implantation of the optical fibre and the determination 
of the optimum time for illumination. However, despite these 
interesting results, efforts have to be made before eventual clin-
ical translation to develop cGMP functionalization of AGuIX 
NPs with synthesis processes compatible with industrial speci-
fications and limitations. Toxicity has also to be tested in GPL 
regulatory studies.
FiRst in mAn
The first in man administration of the AGuIX NPs was performed 
during the NanoRAD clinical trial (NCT02820454).77 NanoRAD 
is a phase Ib clinical trial ongoing at CHU Grenoble Alpes aimed 
at treating multiple brain metastases by whole brain RT (10 × 
3 Gy over 3 weeks max) in combination with AGuIX Nps (one 
injection 4 h before the first session of RT). The NanoRAD 
trial was designed as a dose escalation phase Ib with five doses 
tested (15, 40, 50, 75 and 100 mg kg−1). The NPs were injected 
in patients with brain metastases originating from four different 
types of cancer: lung (NSCLC), melanoma, colon and breast. For 
each type of cancer, a targeting of the metastases by AGuIX NPs 
was observed due to the EPR effect (Figure 13). Interestingly, all 
the metastases already detected by conventional T1 MRI contrast 
agent were also detected by AGuIX NPs. To conclude, besides 
its strong local radioenhancing effect, one of the main proper-
ties of AGuIX nanodrug that makes it such strong candidate as 
a radiosensitizer is its ability to pass through the blood brain 
barrier selectively in brain metastases leading to the possibility 
of a differential response between the tumour and dose-limiting 
normal tissue.
The NanoCOL clinical trial (NCT03308604) has been accepted 
recently by French regulatory office. NanoCOL is a Phase Ib 
clinical trial ongoing in Gustave Roussy institute (Ville-
juif).78 It is aimed to treat advanced cervical cancer by RT and 
brachytherapy in association with AGuIX NPs and cisplatin 
(CDPP) (Figure 14). During the protocol, three injections of 
AGuIX NPs will be delivered before the first irradiation at 
Week 1, at the beginning of Week 3 and before brachytherapy. 
Conventional RT will be delivered during 5 weeks (45 Gy, 25 
sessions) and concomitant weekly i.v. administration of CDPP 
(40 mg m−2) will be performed. Brachytherapy (15 Gy) will be 
delivered in 2 weeks. First patient of NanoCOL clinical trial 
has been included in May 2018.
conclusion
AGuIX NPs are one of the few inorganic NPs that have been 
translated to the clinic for theranostic applications. Besides 
their MRI positive contrast agent properties, they display 
high radiosensitizing potential at a very small concentration 
Figure 14. Protocol of the NanoCOL Phase Ib clinical trial.
Figure 13. Illustration of 3D MR imaging of the NanoRAD clinical trial obtained 2 h after i.v. administration of AGuIX NPs. Brain 
metastases (issued from melanoma, non-small cell lung cancer NSCLC, colon cancer and breast cancer) are targeted by AGuIX 
NPs while no enhancement of the signal is observed in healthy tissues. NPs, nanoparticles.
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